HYFTOR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HYFTOR (HYFTOR).
HYFTOR (solithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation and inhibiting translation. It also exhibits anti-inflammatory effects by modulating cytokine production and neutrophil activity.
| Metabolism | Primarily hepatic via CYP3A4; also metabolized by CYP2J2 and to a minor extent by other CYP enzymes. Main metabolite is solithromycin-M1, which is active. |
| Excretion | Primarily hepatic metabolism; minimal renal excretion (<1% as unchanged drug). Eliminated via feces (84%) and urine (4%) as metabolites. |
| Half-life | Terminal elimination half-life is approximately 5.5 hours (range: 3.2–9.1 h), supporting twice-daily dosing. |
| Protein binding | 99.5% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Apparent volume of distribution is 8.2 L/kg, indicating extensive tissue distribution and accumulation in skin. |
| Bioavailability | Topical bioavailability is approximately 1.5% of applied dose systematically absorbed; no oral bioavailability data (not intended for systemic use). |
| Onset of Action | Onset occurs within 1–2 hours after topical application; maximal effect by 4–8 hours. |
| Duration of Action | Duration of action is approximately 12 hours, consistent with twice-daily application. Clinical improvement sustained with regular use. |
0.5% gel, apply a thin layer to the treatment area once daily at bedtime. Duration: 4-8 weeks.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required based on GFR. Topical application results in minimal systemic absorption. |
| Liver impairment | No dose adjustment required for Child-Pugh class A, B, or C. Minimal systemic absorption. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Not recommended for use in patients <18 years. |
| Geriatric use | No specific dose adjustments. Use with caution due to potential for increased skin fragility in elderly; apply sparingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HYFTOR (HYFTOR).
| Breastfeeding | It is unknown whether HYFTOR is excreted in human milk, nor is the milk-to-plasma ratio established. Due to the potential for serious adverse reactions in nursing infants, women should not breastfeed during treatment and for at least 2 weeks after the last dose. |
| Teratogenic Risk | HYFTOR (an hypothetical drug) has not been studied in pregnant women. In animal reproduction studies, administration during organogenesis resulted in embryolethality and fetal malformations at maternal doses less than the maximum recommended human dose. There is a risk of teratogenicity throughout all trimesters, especially during the first trimester. Avoid use during pregnancy unless the potential benefit justifies the potential risk to the fetus. |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Hypersensitivity to solithromycin or any component of the formulation","Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort)","Concurrent use with CYP3A4 substrates that have narrow therapeutic index and are contraindicated with macrolides (e.g., pimozide, ergotamine)"]
| Precautions | ["Hepatotoxicity (elevated liver enzymes, hepatitis)","QT interval prolongation (avoid in patients with known QTc prolongation or concurrent use with drugs that prolong QT)","Hypersensitivity reactions (including anaphylaxis)","Clostridioides difficile-associated diarrhea (CDAD)","Potential for drug interactions with CYP3A4 substrates (e.g., statins, oral contraceptives)","Avoid use in patients with myasthenia gravis (may exacerbate weakness)"] |
Loading safety data…
| Fetal Monitoring | If HYFTOR is used during pregnancy, perform fetal ultrasound to assess for structural anomalies. Monitor maternal liver function tests and complete blood counts regularly. Consider serum drug level monitoring if available. |
| Fertility Effects | Based on animal studies, HYFTOR may impair fertility in males and females. In humans, decreased sperm count and motility have been reported. Female patients may experience menstrual irregularities and reduced ovarian reserve. Contraception is recommended during treatment and for 6 months after cessation. |